Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchUDCAUDCA (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Ursodeoxycholic acid for COVID-19: real-time meta analysis of 12 studies

@CovidAnalysis, February 2024, Version 11V11
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Brevini (PSM) 94% 0.06 [0.00-2.37] death 0/31 14/155 Improvement, RR [CI] Treatment Control Brevini (PSM) 67% 0.33 [0.05-2.43] ventilation 1/31 15/155 Brevini (PSM) 75% 0.25 [0.03-1.79] ICU 1/31 20/155 Brevini (PSM) 40% 0.60 [0.37-0.99] hosp. 11/31 91/155 John 46% 0.54 [0.41-0.71] cases 1,607 (n) 1,607 (n) Li 40% 0.60 [0.15-2.48] hosp. 3/225 5/225 Li 29% 0.71 [0.65-0.79] hosp. time 225 (n) 225 (n) Li 80% 0.20 [0.02-1.70] severe case 1/225 5/225 Li 80% 0.20 [0.10-0.38] m/s case 10/225 50/225 Li (PSM) 11% 0.89 [0.77-0.97] cases 192/225 212/225 Yu 38% 0.62 [0.38-1.01] no recov. 62 (n) 45 (n) Liu -2% 1.02 [0.83-1.25] cases 95/146 51/80 Liu -4% 1.04 [0.90-1.20] cases 118/146 62/80 Okushin (PSM) 17% 0.83 [0.40-1.74] symp. case 10/47 12/47 Okushin (PSM) 0% 1.00 [0.57-1.76] cases 16/47 16/47 Okushin (PSM) 0% 1.00 [0.46-2.18] symp. case 10/47 10/47 Okushin (PSM) -7% 1.07 [0.60-1.90] cases 16/47 15/47 Ojeda‐Fernández -7% 1.07 [0.79-1.44] death 54/219 259/1,141 Ojeda‐Fernández 4% 0.96 [0.25-3.65] ICU 3/219 15/1,141 Ojeda‐Fernández -6% 1.06 [0.83-1.36] hosp. 77/219 393/1,141 Ojeda‐Fernández 3% 0.97 [0.81-1.16] cases n/a n/a Ojeda‐Fernández -1% 1.01 [0.81-1.27] cases 83/1,687 399/7,930 Ojeda‐Fernández 9% 0.91 [0.66-1.19] cases 43/1,125 273/6,731 Marrone -7% 1.07 [0.69-1.64] death 26/108 118/521 Ming 13% 0.87 [0.77-0.98] cases 185/3,804 297/5,060 high vs. low Gao 12% 0.88 [0.75-0.99] cases 114/163 183/230 Costello 24% 0.76 [0.53-1.08] death 7,225 (n) 4,080 (n) Costello 19% 0.81 [0.68-0.96] hosp. 7,225 (n) 4,080 (n) Costello 21% 0.79 [0.67-0.93] death/hosp. 7,225 (n) 4,080 (n) Corpechot -54% 1.54 [0.44-5.40] death 3/1,322 13/8,825 Corpechot 19% 0.81 [0.29-2.28] ICU 4/1,322 33/8,825 Corpechot 40% 0.60 [0.29-1.24] hosp. 1,322 (n) 8,825 (n) Corpechot 52% 0.48 [0.20-1.19] hosp. 6/1,322 80/8,825 Corpechot 7% 0.93 [0.26-3.29] hosp. case control Ursodeoxycholic acid COVID-19 outcomes c19early.org February 2024 Favors ursodeoxycholic acid Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit